The First Iranian Case of N-acetyl-glutamate Synthase (NAGS) Deficiency Treated with N-carbamylglutamate

Sayarifard F¹, Hadipour F², Hadipour Z², Häberle J³, Shafeghati Y², Sagheb S⁴ and Sarkhail P^2,

¹Pediatric Endocrinology and Metabolism, Children Medical Center, Tehran University, Tehran, Iran

²Genetic and Metabolic Department, Sarem Fertility & Infertility Research Center and Hospital, Tehran, Iran

³Division of Metabolism and Children’s Research Centre, University Children's Hospital Zurich

⁴Neonatal department, Children Medical Center, Tehran University, Tehran, Iran

Cite this paper

Sayarifard F, Hadipour F, Hadipour Z, Häberle J, Shafeghati Y, Sagheb S and Sarkhail P. The First Iranian Case of N-acetyl-glutamate Synthase (NAGS) Deficiency Treated with N-carbamylglutamate. American Journal of Medical Case Reports. 2016; 4(12):384-388. doi: 10.12691/AJMCR-4-12-4

Abstract

Background: N-acetyl-glutamate synthase (NAGS) deficiency is a rare cause of severe neonatal hyperammonemia. Case report: An 8-day old boy, who was born of non-consanguineous Iranian parents by cesarean section, was admitted to the neonatal intensive care unit due to poor feeding, unconsciousness, and seizures. High Ammonia (920 µmol/L, ref. < 100), high plasma glutamine (1628.6 µmol/L, ref. 410-960) and alanine (1151.5 µmol/L, ref. 200-600), low plasma citrulline (6.6 µmol/L, ref. 8-47) and arginine (26.7 µmol/L, ref. 20-160), without orotic aciduria (orotic acid in urine below detection limit) was revealed in metabolic work-up. Based on these results carbamoyl-phosphate synthetase 1 (CPS1) or NAGS deficiency were suspected. The infant was treated by peritoneal dialysis, intravenous sodium benzoate, L-arginine, and oral sodium phenylbutyrate and ammonia declined to 390 µmol/Lafter 10 days. Results: The genetic analysis in the patient and parents confirmed the NAGS deficiency with a novel heterozygous maternal missense mutation in exon 5 c.1172T>G (p.Leu391Arg) and the known change in exon 6c.1450T>C (p.Trp484Arg) on the paternal allele. Carglumic acid (Carbaglu®, Orphan Europe Recordati, Paris, France) was started and ammonia declined to normal (55 µmol/l) after 24 hours, for the first time ever in the patient. Based on the severe neurological impairment due to the initial hyperammonemic crisis and difficulties to access to the drug in Iran, a decision was made with the parents to stop treatment with carglumic acid (while sodium benzoate and sodium phenylbutyrate were continued) and the patient died five days later due to hyperammonemic decompensation. Conclusion: NAGS deficiency, although rare, seems to be panethnic. Thus, in case of hyperammonemia without orotic aciduria but with low plasma citrulline, NAGS deficiency should be considered and a trial with carglumic acid started as early as possible. Our case demonstrates that the prognosis of neonatal onset NAGS deficiency largely depends on early recognition and start of therapy.

Keywords

Urea cycle disorder, NAGS deficiency, N-carbamylglutamate, hyperammonemia

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Bachmann. C, Krahenbuhl. S, Colombo J.P,Schubiger. G, Jaggi K.H, Tönz. O. N-acetylglutamate synthetase deficiency: a disorder of ammonia detoxification, N. Engl. J. Med. 1981; 304: 543.
[2]	Tuchman. M, Caldovic L, Daikhin. Y, Horyn.O, Nissim. I, Korson. M, Burton. B, Yudkoff. M. N- carbamylglutamate markedly enhances ureagenesis in N-acetylglutamate deficiency and propionic acidemia as measured by isotopic incorporation and blood biomarkers. Pediatr Res 2008; 64: 213-217.
[3]	Häberle. J, Schmidt. E, Pauli. S, Kreuder. J.G, Plecko. B, Galler. A, Wermuth. B, Harms. E, Koch. H.G. Mutation analysis in patients with N-acetylglutamate synthase deficiency, Hum. Mutat. 2003; 21: 593-597.
[4]	Caldovic. L, Morizono. H, Gracia Panglao. M.G, Gallegos. R, Yu. X, Shi. D, Malamy. MH, Allewell. NM, Tuchman. M. Cloning and expression of the human N-acetylglutamate synthase gene. Biochem Biophys Res Commun 2002; 299:581-586.
[5]	Caldovic. L, Morizono. H, Panglao. M.G, Cheng. S.F,Packman. S, Tuchman. M. Null mutations in the N-acetylglutamate synthase gene associated with acute neonatal disease and hyperammonemia, Hum. Genet. 2003; 112: 364-368.
[6]	Caldovic. L, Morizono. H, Panglao. MG, Lopez. GY, Shi. D, Summar. ML, Tuchman. M. Late onset N-acetylglutamate synthase deficiency caused by hypomorphic alleles. Hum Mutat 2005; 25: 293-298.
[7]	Brusilow. SW, Horwich. AL. Urea cycle enzymes. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill. 2001. p 1909-1963.
[8]	Guffon. N, Schiff. M, Cheillan. D, Wermuth. B, Haberle. J, Vianey-Saban C. Neonatal hyperammonemia: the N-carbamoyl-L-glutamic acid test. J Pediatr 2005; 147:260-262.
[9]	Caldovic. L, Morizono. H, Tuchman. M. Mutations and polymorphisms in the human N-acetylglutamate synthase (NAGS) gene. Hum Mutat 2007; 28: 754-759.
[10]	Guffon. N, Vianey-Saban. C, Bourgeois. J, Rabier. D, Colombo. JP, Guibaud. P. A new neonatal case ofN-acetylglutamate synthase deficiency treated by carbamylglutamate. J Inherit Metab Dis 1995; 18: 61.
[11]	Bachmann. C, Colombo. JP, Jaggi. K. N-acetylglutamate synthetase (NAGS) deficiency: diagnosis, clinical observations and treatment. Adv Exp Med Biol. 1982; 153: 39-45.
[12]	Häberle. Jand Koch. H.J. Genetic approach to prenatal diagnosis in urea cycle defects. Prenat Diagn 2004; 24: 378-383.
[13]	Grody. WW, Chang. RJ, Panagiotis. NM, Matz. D, Cederbaum. SD.. Menstrual cycle and gonadal steroid effects on symptomatic hyperammonaemia of urea-cycle-based and idiopathic etiologies. J Inherit Metab Dis 1994; 17:566-574.
[14]	Caldovic. L, Morizono. H, Daikhin. Y, Nissim. I, McCarter. RJ, Yudkoff. M, Tuchman. M. Restoration of ureagenesis in N-acetylglutamate synthase deficiency by N-carbamylglutamate. J Pediatr 2004; 145: 552-554.
[15]	Burlina. AB, Bachmann. C, Wermuth. B, Bordugo. A, Ferrari. V, Colombo. JP, Zacchello. F. Partial N-acetylglutamate synthetase deficiency: a new case with uncontrollable movement disorders. J Inherit Metab Dis 1992; 15:395-398.
[16]	Bachmann. C, Brandis. M, Weissenbarth-Riedel. E, Burghard. R, Colombo. JP. N-acetylglutamate synthetase deficiency, a second patient. J Inherit Metab Dis 1988; 11: 191-193.
[17]	Bachmann. C, Krahenbuhl. S, Colombo. JP. Purification and properties of acetyl-CoA: L-glutamate N-acetyltransferase from human liver. Biochem J 1982; 205:123-127.
[18]	Ah Mew. N and Caldovic. L. N-acetylglutamate synthase deficiency: an insight into the genetics, epidemiology, pathophysiology, and treatment. The Application of Clinical Genetics 2011: 4 127-135.
[19]	Caldovic. L, Morizono. H, and Tuchman. M. Mutations and Polymorphisms in the Human N-Acetylglutamate Synthase (NAGS) Gene. Human Mutation 2007; 28(8), 754-759.
[20]	Heibel. S.K, Ah Mew. N, Caldovic. L, Daikhin. Y, Yudkoff. M, and Tuchman. M. N-Carbamyl glutamate enhancement of ureagenesis leads to discovery of a novel deleterious mutation a newly defined enhancer of the NAGS gene and to effective therapy. Hum Mutat. 2011; 32(10): 1153-1160.
[21]	Ah Mew. N, Caldovic. L. N-acetylglutamate synthase deficiency: an insight into the genetics, epidemiology, pathophysiology, and treatment. Appl Clin Genet. 2011; 24; 4: 127-35.
[22]	Morris. AA, Richmond. SW, Oddie. SJ, Pourfarzam. M, Worthington. V, Leonard. JV. N-acetylglutamate synthetase deficiency: favorable experience with carbamylglutamate. J Inherit Metab Dis 1998; 21: 867-868.
[23]	Schmidt. E, Nuoffer. JM, Häberle. J, Pauli. S, Guffon. N, Vianey-Saban. C, Wermuth. B, Koch. HG. Identification of novel mutations of the human N-acetylglutamate synthase gene and their functional investigation by expression studies. Biochim Biophys Acta. 2005; 1740(1): 54-59.
[24]	Nordenstrom. A, Halldin. M, Hallberg. B, Alm. J. A trial with N-carbamylglutamate may not detect all patients with NAGS deficiency and neonatal onset. J Inherit Metab Dis. 2007; 30(3): 400.
[25]	Gessler. P, Buchal. P, Schwenk. HU, Wermuth. B. Favorable long- term outcome after immediate treatment of neonatal hyperammonemia due to N-acetylglutamate synthase deficiency. Eur J Pediatr. 2010; 169(2): 197-199.
[26]	Colombo. JP. N-acetylglutamate synthetase (NAGS) deficiency. Adv Exp Med Biol. 1994; 368: 135-143.
[27]	Häberle. J. Role of carglumic acid in the treatment of acute hyperammonemia due to N-acetylglutamate synthase deficiency. Therapeutics and Clinical Risk Management 2011:7 327-332.